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ABSTRACT 9 
The effect of fermentation on the antithrombotic properties of polar lipids in ovine milk has 10 
been assessed through the production of yoghurts. The total lipids (TL), total neutral lipids 11 
(TNL), and total polar lipids (TPL) were extracted. The fatty acid profiles of all yoghurt polar 12 
lipids were analysed by GC-MS. The levels of MUFA increased, but there was a reduction in 13 
PUFA as milk was fermented to yoghurt. The bioactivity of each lipid extract was assessed 14 
against platelet-activating factor (PAF) induced platelet aggregation. All yoghurt polar lipids 15 
exhibited potent antithrombotic activities with IC50 values ranging from 45–77 µg. Shotgun 16 
metagenomics determined the species-level microbial composition and functional potential of 17 
the yoghurts. Yoghurts containing L. acidophilus seem to correlate with greater bioactivity. 18 
Several phospholipid biosynthetic genes have been identified in the most antithrombotic 19 
yoghurts. This study has demonstrated that fermentation enhances the antithrombotic 20 
properties of yoghurt polar lipids against PAF. 21 
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Highlights:  30 
• Fermentation alters the polar lipid fatty acid profile of ovine milk 31 
• Specific starter cultures alter the antithrombotic properties of ovine milk in the 32 
production of yoghurts  33 
• S. thermophilus and L. acidophilus alter the anti-PAF and antithrombotic properties of 34 
yoghurts 35 
• Genes associated with phospholipid biosynthesis have been detected in the most 36 
bioactive yoghurts 37 
 38 
 39 
1. Introduction 40 
Maladaptive diet and lifestyle play a significant role in the development of chronic diseases 41 
such as cardiovascular disease (CVD), insulin resistance, obesity, and cancer (Mozaffarian, 42 
2016). Diet and lifestyle are key modifiable risk factors for the prevention of CVD (Lordan, 43 
Tsoupras, Mitra, & Zabetakis, 2018). In 2016, CVD was responsible for 17.7 million deaths, 44 
where 80% of CVD events were either a myocardial infarction or stroke (World Health 45 
Organization, 2017), of which dietary risk factors accounted for 49% of all CVD deaths (Meier 46 
et al., 2018). Dairy products were long perceived as negative dietary components by public, 47 
scientific, and media circles, as they are energy dense foods rich in saturated fatty acids (SFA), 48 
which can increase cholesterol levels (Lamarche et al., 2016; Lordan & Zabetakis, 2017a). 49 
Therefore, low-fat or non-fat dairy products were encouraged by many dietary 50 
recommendations in order to reduce to lower cholesterol levels (Lordan, Tsoupras, Mitra, et 51 
al., 2018). However, recent research indicates that dairy products may be neutral or even 52 
beneficial for cardiovascular health, and may not have significant effects on blood cholesterol 53 
levels (Labonté, Couture, Richard, Desroches, & Lamarche, 2013; Lordan, Tsoupras, Mitra, et 54 
al., 2018; Lordan & Zabetakis, 2017a; Thorning et al., 2016). Further evidence indicates that 55 
fermented dairy products may be more beneficial for health than non-fermented dairy products, 56 
especially against a number of cardiometabolic risk factors such as hypertension, cholesterol 57 
levels, and impaired glucose tolerance (Lordan, Tsoupras, Mitra, et al., 2018).   58 
Yoghurt consumption is associated with numerous health benefits including; 59 
preventing type II diabetes mellitus, obesity, metabolic syndrome, and CVD (Gijsbers et al., 60 
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2016; Lordan, Tsoupras, Mitra, et al., 2018; Sayon-Orea, Martínez-González, Ruiz-Canela, & 61 
Bes-Rastrollo, 2017; Wu & Sun, 2017). Bovine milk accounts for 85% of the total global milk 62 
production (Balthazar et al., 2017), however ovine milk and yoghurts provide a superior 63 
nutritional alternative. Ewe’s milk and dairy products are not commonly consumed outside of 64 
the Mediterranean basin, and are considered a delicacy in many countries (Lordan & Zabetakis, 65 
2017b). Ovine milk owes it nutritional superiority over bovine and caprine milk due to the 66 
higher levels of protein, lipid, minerals, and vitamins essential to human health (Balthazar et 67 
al., 2017; Lordan, Tsoupras, Mitra, et al., 2018). The most predominant fatty acid in ovine milk 68 
and yoghurts are oleic acid (18:1), palmitic acid (16:0), and myristic acid (14:0) (Balthazar et 69 
al., 2017). Diets high in oleic acid decrease low-density lipoprotein (LDL) cholesterol levels, 70 
whereas high-density lipoprotein (HDL) cholesterol levels are not significantly affected 71 
(Lordan & Zabetakis, 2017b; Molkentin, 2000). It has recently be shown that ovine yoghurt 72 
consumption does not affect the lipid profile of healthy individuals (Olmedilla-Alonso et al., 73 
2017). In addition, a recent crossover study has demonstrated a moderate attenuation of several 74 
inflammatory markers in participants with a high total cholesterol/HDL cholesterol ratio 75 
following ovine yoghurt consumption (Redondo et al., 2018). Evidently, these neutral effects 76 
on serum cholesterol levels, putative anti-inflammatory effects, and antithrombotic effects 77 
(Megalemou et al., 2017; Tsorotioti et al., 2014) indicate that ovine dairy products may be 78 
beneficial for human cardiovascular health upon consumption and thus warrant further 79 
investigation (Lordan, Tsoupras, Mitra, et al., 2018).   80 
Ovine dairy products also possess potent antithrombotic properties that are attributed 81 
to their polar lipid content (Lordan & Zabetakis, 2017a). The polar lipid content of ovine milk 82 
is approximately 9.4-35.5 mg/100g of raw milk. The polar lipid fraction contains 83 
phosphatidylcholine (PC), phosphatidylethanolamine (PE), and sphingomyelin (SM), which 84 
are present in abundance with lower quantities of phosphatidylserine (PS) and 85 
phosphatidylinositol (PI), which is comparable to other ruminant species (Lordan, Tsoupras, 86 
& Zabetakis, 2017; Park, 2009). Although the phospholipid fraction of ovine milk is 87 
quantitatively a minor constituent of the overall lipid content, it possesses techno-functional 88 
and nutritional properties that are implicated in several physiological processes and are 89 
beneficial for health (Lordan et al., 2017).  90 
Systemic inflammation is the key biochemical process implicated in the initiation and 91 
progression of atherosclerosis (Moss, Williams, & Ramji, 2018). Circulating inflammatory 92 
mediators such as PAF actively contribute to vascular and atheromatous change (Da Silva & 93 
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Rudkowska, 2015; Lordan et al., 2017; Tsoupras, Lordan, & Zabetakis, 2018). PAF is a potent 94 
proinflammatory phospholipid mediator that is implicated in all stages of atherosclerosis that 95 
can lead to a major cardiovascular event. PAF and PAF-like molecules act solely through their 96 
binding to a unique G-protein coupled seven transmembrane receptor known as the PAF-97 
receptor (PAF-R), that subsequently triggers multiple intracellular pathways (Castro Faria 98 
Neto, Stafforini, Prescott, & Zimmerman, 2005; Lordan et al., 2017; Tsoupras, Lordan, & 99 
Zabetakis, 2018). PAF plays a key role in various physiological responses such as modulation 100 
of normal inflammatory responses and the regulation of blood pressure and coagulation 101 
(Lordan et al., 2017; Palur Ramakrishnan, Varghese, Vanapalli, Nair, & Mingate, 2017). 102 
Therapeutic approaches to the proinflammatory effects of PAF focus on disrupting PAF/PAF-103 
R interactions through competitive and non-competitive displacement of PAF from the receptor 104 
(Lordan, Tsoupras, & Zabetakis, 2018). Dietary PAF inhibitors have been identified in the 105 
polar lipids of marine (Lordan et al., 2017; Sioriki, Smith, Demopoulos, & Zabetakis, 2016), 106 
meat (Poutzalis, Lordan, Nasopoulou, & Zabetakis, 2018), and dairy sources (Megalemou et 107 
al., 2017; Poutzalis et al., 2016). In particular, ovine dairy products possess potent PAF 108 
inhibitors (Tsorotioti et al., 2014).  109 
It has been postulated that fermentation increases the bioactivity of phospholipids 110 
against PAF (Antonopoulou, Semidalas, Koussissis, & Demopoulos, 1996; Lordan & 111 
Zabetakis, 2017a). However, to date, this has not been definitively established. Thus, the aim 112 
of this study was to evaluate the effect of bacterial fermentation on the polar lipid composition 113 
and antithrombotic activity of ovine milk and yoghurts via PAF-induced platelet aggregation 114 
on human platelets in vitro. Furthermore, shotgun metagenomics was employed to characterise 115 
the species-level microbial composition of the yoghurts, and to determine if the detected 116 
species contained genes associated with fatty acid and/or lipid metabolism.  117 
 118 
2. Materials and methods 119 
2.1. Chemicals and reagents 120 
All organic solvents and glassware used in the lipid extraction and isolation process were 121 
purchased from Fisher Scientific Ireland Ltd. (Dublin, Ireland). All chemical reagents used for 122 
platelet aggregometry and lipid standards for GC-MS were purchased from Sigma-Aldrich 123 
(Wicklow, Ireland). All platelet aggregometry consumables were purchased from Labmedics 124 
LLP (Abingdon on Thames, U.K.). All GC-MS consumables were purchased from Apex 125 
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Scientific Ltd. (Kildare, Ireland). The PowerSoil DNA Isolation kit and PowerNad tubes were 126 
purchased from Cambio (Cambridge, United Kingdom). Lysozyme, mutanolysin and 127 
proteinase K were purchased from Sigma-Aldrich (Wicklow, Ireland). The Qubit High 128 
Sensitivity DNA assay was obtained from Life Technologies (ThermoFisher Scientific, Dublin, 129 
Ireland). 130 
 131 
2.2.  Milk processing & yogurt production 132 
A fresh, commercial, pasteurised, and homogenised ewe’s whole milk was obtained from 133 
Rockfield Dairy Ltd. (Claremorris, Co Mayo, Ireland). Milk was obtained from a bulk tank 134 
containing milk from the Friesland and Lacaune breed of dairy ewe, between March and July 135 
2016. The sheep were fed a forage based diet consisting of mainly grass silage or fresh grass, 136 
supplemented with cereal at the time of milking, which is typical of the small sheep dairy 137 
industry in Ireland; however, atypical in Europe where the diet mainly consists of cereal. The 138 
collected milk was pasteurised on site by heating to 91 °C for 15 seconds and then was cooled 139 
to 42 °C before being packaged and refrigerated (4 °C ± 1 °C) for transport to the laboratory. 140 
For yoghurt production, all milk samples were heated to 42 °C in pre-sterilised conical flasks 141 
in a water bath (Grant JB NV, Cambridgeshire, UK) and held at that temperature throughout 142 
the yogurt fermentation process. All yogurts (A-E) were inoculated with specific starter 143 
cultures as indicated in Table 1. When inoculated, the milk was mixed thoroughly and the 144 
temperature was held at 42 °C. The pH was monitored until the yogurt fermentation reached 145 
between 4.4 – 4.6 pH units, then the fermentation was stopped by cooling the yogurts to 4 °C. 146 
All yoghurts were made in triplicate. The yogurts were then transferred to glass media bottles 147 
and stored at -20 °C until required for analysis or a maximum of six weeks.    148 
 149 
2.3.Yogurt cultures 150 
The bacterial cultures used to manufacture the yogurts detailed in Table 1 were obtained in 151 
freeze dried form. Mother culture solutions were produced from the freeze dried cultures. The 152 
cultures used for the production of yogurts were kindly provided by Chr-Hansen (Cork, 153 
Ireland) and Orchard Valley Dairy Supplies (Worcestershire, UK).  154 
*Insert Table 1 Here* 155 
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2.4.Extraction & isolation 156 
The total lipids (TL) of all yogurt samples and milk were extracted from 100 g of sample 157 
according to the method of Bligh and Dyer (1959). One tenth of the TL was stored in sealed 158 
vials at −20 °C, while the TL was then further separated into total neutral lipids (TNL) and 159 
total polar lipids (TPL) by counter-current distribution (Galanos & Kapoulas, 1962). All lipid 160 
extracts were stored devoid of solvent in sealed vials under a nitrogen atmosphere at -20 °C. 161 
All extractions were carried out in triplicate.  162 
 163 
2.5. In vitro human biological assay 164 
Blood was obtained from healthy human volunteers (n = 12) as previously described 165 
(Tsoupras, Lordan, Demuru, et al., 2018; Tsoupras, Zabetakis, & Lordan, 2019). The Ethics 166 
Committee of the University of Limerick approved the protocol and it was performed in 167 
accordance with the Declaration of Helsinki. Healthy donors were fully aware that their blood 168 
samples were used in the study and written consent was provided to the specialised 169 
phlebotomist. All fasting blood samples provided were from participants not receiving anti-170 
platelet therapy. A total of 50 ml of blood was drawn from the median cubital vein via 171 
venepuncture using a 20 G safety needle into sodium citrate anticoagulant S-monovettes using 172 
the aspiration method (0.106 mol/L in a 1:10 ratio of citrate to blood; Sarstedt Ltd., Wexford, 173 
Ireland). For plasma isolation, blood was drawn into evacuated sodium citrate Monovettes 174 
(0.106 mol/L in a 1:10 ratio of citrate to blood; Sarstedt Ltd., Wexford Ireland) and rested at 175 
room temperature for 15 minutes followed by immediate centrifugation at 194 x g for 18 176 
minutes at 24 °C with no brake applied in order to obtain the supernatant platelet-rich plasma 177 
(PRP). A second centrifugation at 1500 x g for 20 minutes at 24 °C was carried out to obtain 178 
the platelet-poor plasma (PPP). All centrifugations were processed using an Eppendorf 5702 R 179 
centrifuge (Eppendorf Ltd., Stevenage, UK). The PRP was standardised to 500,000 platelets 180 
µl-1 using a Shimadzu UV-1800 spectrophotometer (Kyoto, Japan), before analysis on a 181 
Chronolog-490 two channel turbidimetric platelet aggregometer, coupled to the accompanying 182 
AGGRO/LINK software package (Chronolog, Havertown, PA, USA). All analyses were 183 
carried out within 2.5 hours of the initial blood draw and PRP was stored at 24 °C before use. 184 
PAF and lipids samples were dissolved in a solution of BSA-saline (2.5 mg BSA/ml saline). 185 
Prior to testing, 250 µl of PRP was added to an aggregometer cuvette at 37 °C with stirring at 186 
1000 rpm, and was calibrated prior to testing using the PPP as a blank. PAF was added to the 187 
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cuvettes in order induce maximum reversible aggregation (2.6 x 10-8 M, final concentration in 188 
the cuvette), and 50% PAF-induced aggregation was calculated. Lipid samples were tested and 189 
IC50 values were calculated as previously described (Tsoupras, Lordan, Demuru, et al., 2018). 190 
All experiments were performed in triplicate using a different donor’s blood for each replicate 191 
to ensure reproducibility following appropriate control tests of the solvents used on human 192 
platelets (saline and BSA-saline solution). The resulting IC50 values were expressed as a mean 193 
value of the mass of lipid (µg) in the cuvette ± standard deviation (SD). This procedure was 194 
informed by the guidelines for light transmission aggregometry by Cattaneo et al. (2013).  195 
 196 
2.6. GC-MS analysis 197 
Fatty acid methyl esters (FAME) were prepared using 35 mg of the TPL of the milk and 198 
yogurt samples in triplicate according to the method of Tsoupras, Lordan, Demuru, et al. (2018) 199 
with slight modifications. In brief, FAME were prepared using a solution of 0.5 M KOH in 90 200 
% CH3OH and extracted with n-hexane. The GC-MS fatty acid analysis was carried out 201 
according the internal standard method as previously described (Tsoupras, Lordan, Demuru, et 202 
al., 2018). The equation that described the curve was: y = 0.0041x + 0.12 with an R2 = 0.9969, 203 
where the ratio of the area of the analyte peak to that of the internal standard (21:0) represents 204 
the y value for the above equation, subsequently the x value represents the analyte 205 
concentration of a selected fatty acid in the lipid sample to be tested. Separation of the FAME 206 
was achieved on an Agilent J&W DB-23 fused silica capillary column (60 m, 0.251 mm, i.d., 207 
0.25 µm; Agilent Technologies, Santa Clara, CA, USA) using a Varian 410-GC coupled to a 208 
Varian 210-MS equipped with a split/splitless injector (Agilent Technologies). The injector 209 
was set at 230 °C with a split ratio of 1:5. The carrier gas was high purity helium with a liner 210 
flow rate of 1 ml/min.  The oven temperature was initially programmed to 100 °C for 5 min, 211 
raised to 240 °C at 3 °C/min, and finally held isothermal at 240 °C for 10 mins. FAME were 212 
identified using 37-component FAME standards mix (Sigma Aldrich, Wicklow, Ireland) by 213 
comparison of the retention times and mass spectra of relative peaks with the aid of the Varian 214 
Star Chromatography Workstation Version 6 software (Agilent Technologies) and a NIST 215 
library (Gaithersburg, MD, USA).  216 
 217 
 218 
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2.7.Total DNA extraction from yogurt 219 
DNA was extracted from 15 ml yoghurt as described by Walsh et al. (2016) with slight 220 
modifications. Yoghurt samples were centrifuged at 5,444 × g for 30 min at 4 °C to pellet the 221 
microbial cells in the liquid. The cell pellet was resuspended in 200 µl of PowerBead solution 222 
from the PowerSoil DNA Isolation kit (Cambio, Cambridge, United Kingdom). The 223 
resuspended cells were transferred to a pre-heated (at 60 °C) PowerBead tube (Cambio, 224 
Cambridge, United Kingdom). A 90 µl volume of 50 mg/ml lysozyme (Sigma-Aldrich, Dublin, 225 
Ireland) and 50 µl of 100 U/ml mutanolysin (Sigma-Aldrich, Dublin, Ireland) were added, and 226 
the sample was incubated at 60 °C for 15 min. A 28 µl volume of proteinase K (20 mg/ml; 227 
Sigma-Aldrich, Dublin, Ireland) was added, and the sample was incubated at 60 °C for a further 228 
15 min. DNA was then purified from the sample by the standard PowerSoil DNA Isolation kit 229 
protocol (Cambio, Cambridge, United Kingdom). 230 
 231 
2.8. Whole-metagenome shotgun sequencing 232 
Whole-metagenome shotgun libraries were fragmented and adaptors and indices added 233 
using the Illumina Nextera XT guide in accordance with manufacturer’s instructions, except 234 
that tagmentation time was increased from 5 min to 7 min. After indexing, the average fragment 235 
size was assessed using an Agilent Bioanalyser High Sensitivity Assay (Agilent) and quantified 236 
using a Qubit High Sensitivity assay (Life Technologies). Samples were then pooled 237 
equimolarly and the final pool was quantified by quantitative PCR using the Kapa Library 238 
Quantification Kit for Illumina (Roche).  The pool was then sequenced on the Illumina MiSeq 239 
sequencing platform in the Teagasc sequencing facility, with a 2 × 300 cycle V3 kit, in 240 
accordance with standard Illumina sequencing protocols. 241 
 242 
2.9. Bioinformatics 243 
Shotgun metagenomic fastq files were processed as described previously (Walsh et al., 244 
2018). Briefly, raw fastq files were converted to unaligned bam files using SAMtools (H. Li et 245 
al., 2009). Duplicate reads were subsequently removed using Picard Tools 246 
(https://github.com/broadinstitute/picard). Next, low quality reads were removed using the 247 
trimBWAstyle.usingBam.pl script from the Bioinformatics Core at UC Davis Genome Center 248 
(https://github.com/genome/genome/blob/master/lib/perl/Genome/Site/TGI/Hmp/HmpSraPro249 
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cess/trimBWAstyle.usingBam.pl). Specifically, reads were trimmed to 200 bp, while all reads 250 
with a quality score less than Q30 were discarded. The resulting fastq files were then converted 251 
to fasta files using the fq2fa option from IDBA-UD (Peng, Leung, Yiu, & Chin, 2012). Species-252 
level analysis was performed using MetaPhlAn2 (Truong et al., 2015), which measures the 253 
abundance of species-specific marker genes in metagenomic reads. Microbial pathway analysis 254 
was performed using HUMAnN2 (Abubucker et al., 2012), which measures the abundances of 255 
UniRef clusters (Suzek et al., 2015) by aligning sequences against the ChocoPhlAn database. 256 
Bacteriocin genes were quantified by aligning reads against the BAGEL3 (van Heel, de Jong, 257 
Montalban-Lopez, Kok, & Kuipers, 2013) bacteriocin database using DIAMOND (Buchfink, 258 
Xie, & Huson, 2015). Hits against the BAGEL3 bacteriocin database were counted with 259 
SAMtools, after which the results were normalised as copies per million. 260 
 261 
2.8. Statistical analysis 262 
All biological experimental analyses were completed in triplicate, and the obtained results were 263 
expressed as a mean value ± standard deviation (SD). One-way analysis of variance (ANOVA) 264 
was employed in order to find the significant statistical differences (p < 0.05) and Fisher’s least 265 
significant difference (LSD) test was used to conduct multiple comparisons of the means (SPSS 266 
Inc., Chicago, 215 IL, USA). For the bioinformatics, statistical analysis was performed in R-267 
3.2.2 (Team R Core, 2013). The vegan package (version 2.3.0) (Oksanen et al., 2007) was used 268 
for Bray-Curtis based multidimensional scaling (MDS) analysis. The ggplot2 package (version 269 
2.2.1) (Wickham, 2016) was used for data visualisation. 270 
 271 
3.  Results  272 
3.1. Lipid extraction 273 
The resulting TL, TNL, and TPL of all yoghurt samples are presented in Table 2. It is clear 274 
from the extraction data that the milk TL is statistically significantly different from all but 275 
yoghurt C. The percentage of TNL in all yoghurts were not statistically significantly different 276 
from each other. The percentage of TPL of the milk was statistically significantly different 277 
from yoghurts A, B, and E, but similar to the other yoghurts. The percentage of TPL of all 278 
yoghurts were not statistically significantly different from each other. This agrees with 279 
previously published data relating to ovine milk and yoghurts (Balthazar et al., 2017; 280 
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Megalemou et al., 2017), where generally the polar lipid content is reported as relatively low 281 
(Lordan et al., 2017).  282 
*Insert Table 2 Here* 283 
 284 
3.2. GC-MS analysis 285 
The fatty acid content of the TPL is shown in Table 3. As a result of fermentation, there seems 286 
to be a trend towards the reduction of PUFA levels and an increase of MUFA levels in the fatty 287 
acids of the polar lipids, whereas the levels of SFA vary depending on the yoghurt produced. 288 
Specifically, there is a statistically significant (p < 0.05) increase in the levels of 16:1, 17:0, 289 
17:1, 18:2 (cis-10, trans-12), 20:4, and 22:5 when milk was fermented to yoghurt. Remarkably, 290 
across all yoghurts there was a statistically significant reduction in the levels of ω3 PUFA in 291 
the TPL as the milk was fermented to yoghurts. This data indicates that fermentation directly 292 
affects the fatty acid composition of milk polar lipids.  293 
*Insert Table 3 Here* 294 
 295 
3.3. Biological assay  296 
The lipid extracts from the milk and yoghurt samples exhibited potent inhibition against PAF-297 
induced platelet aggregation on human PRP in vitro (Table 4). The TNL of various yoghurts 298 
exhibited a poor inhibitory effect against platelet aggregation. However, some had moderate 299 
inhibitory effects. Similarly the TL exhibited moderate inhibitory effects against PAF-induced 300 
platelet aggregation. Notably, the TL of the yoghurts were considerably more bioactive than 301 
the TNL extracts but not as bioactive as the TPL extracts. This indicates that there is a 302 
synergistic effect between the TNL and TPL. It is clear from Table 4 that the TPL extract were 303 
the most inhibitory against PAF. Ovine milk TPL exhibited the highest IC50 values, indicating 304 
that this sample possessed the lowest antithrombotic activity. Yoghurts B and D possessed the 305 
lowest IC50 values, where the IC50 of yoghurt D was statistically significantly lower than all 306 
other samples tested. 307 
*Insert Table 4 Here* 308 
  309 
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3.4. Yoghurt microbial composition 310 
MetaPhlAn2, which measures the abundance of species-specific marker genes in shotgun 311 
metagenomic reads, was used to determine and confirm the composition of the yoghurts made 312 
with commercial starter cultures. The genera and species detected in the yoghurts and their 313 
relative abundances are depicted in Fig. 1. In all of the yoghurts produced, S. thermophilus was 314 
the most dominant species, L. delbrueckii subsp. bulgaricus was the second most abundant 315 
species in yoghurts A and B. L. acidophilus was the third most abundant species present in 316 
yoghurts B (4.8%) and C (6.2%) and was the second most abundant in yoghurt D (4.9%). B. 317 
animalis was the second most abundant species (6.9%) present in yoghurt C. In yoghurt E, S. 318 
thermophilus was the predominant species with L. paracasei present in low proportions (<1%) 319 
along with E. durans (1.9%).  320 
*Insert Fig. 1. Here* 321 
 322 
3.5. Gene composition of the yoghurts 323 
Functional analysis of the shotgun metagenomic data was performed using HUMAnN2 324 
(https://bitbucket.org/biobakery/humann2). The abundances of Gene Ontology (GO) and the 325 
abundance of level-4 EC categories of interest are presented in Fig. 2 and 3 respectively. The 326 
abundances of genes associated with phospholipid biosynthesis and metabolism were detected 327 
in all of the yoghurts. According the data in Fig. 2., the abundance of GO terms associated with 328 
polar lipid biosynthesis and metabolism are associated with the presence of S. thermophilus 329 
and L acidophilus indicating that these microbes have the capacity to alter the polar lipid 330 
composition of the milk and yoghurts. Similarly, the data in Fig. 3. indicates that both S. 331 
thermophilus and L acidophilus have the greatest capacity to biosynthesise fatty acids and 332 
phospholipids according to the abundance of level-4 EC categories of interest.   333 
*Insert Fig. 2. Here* 334 
*Insert Fig. 3. Here* 335 
3.6. Bacteriocins 336 
Bacteriocins are ribosomally synthesised antimicrobial peptides produced by several bacterial 337 
species that generally inhibit strains closely related to the producer in order to compete within 338 
their specific ecological niche (O'Shea, Cotter, Stanton, Ross, & Hill, 2012). However, their 339 
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mechanisms of action vary considerably due to their structural diversity. As depicted in Fig. 340 
4., it is clear that the microbes present in the yoghurts possess the genetic capacity to produce 341 
a variety of type II and type III bacteriocins. Notably, yoghurt D, C, and E had a greater number 342 
of hits per class of bacteriocin, which may correlate with greater bioactivity against platelet 343 
aggregation in these yoghurts.  344 
*Insert Fig. 4. Here*  345 
 346 
4. Discussion 347 
 The microbial composition of the yoghurts were assessed following fermentation (Fig. 348 
1A). S. thermophilus was the most dominant species in all of the yoghurts produced, followed 349 
by L. delbrueckii subsp. bulgaricus, which was the second most abundant species in yoghurts 350 
A and B. L. acidophilus was the third most abundant species present in yoghurt B (4.8%) and 351 
C (6.2%) and was the second most abundant in yoghurt D (4.9%). The second most abundant 352 
species present in yoghurt C was B. animalis (6.9%). Although L. paracasei was added to 353 
yoghurt E, this species was present in low proportions (< 1%) in the final yoghurt. Furthermore, 354 
E. durans was also detected in yoghurt E (1.9%). This is a non-pathogenic bacterial species of 355 
human, animal or environmental origin that is often identified in various dairy products and 356 
may be probiotic (Andrighetto et al., 2001). Its presence may be explained by the fact that 357 
enterococci are generally present in higher amounts in caprine and ovine milk (Del Pozo, Gaya, 358 
Medina, Rodríguez-Marín, & Nuñez, 1988) and E. durans in particular is resistant to damage 359 
by heat treatment (McAuley, Gobius, Britz, & Craven, 2012). It is unclear what prevented the 360 
growth of L. paracasei, as generally this species is grown in the presence of the other lactic 361 
acid bacteria present. However, temperature may play a role for its lower abundance as 362 
previous research indicates that this species tends to favour growth below 40 °C at an optimum 363 
of 37 °C (Collins, Phillips, & Zanoni, 1989), in contrast to the other organisms present, which 364 
require 42 °C according to the manufacturers guidelines. Irrespective of these possibilities, 365 
yoghurt E possessed a different microbial composition in comparison to the other yoghurts, 366 
which is characterised by a high proportion of S. thermophilus. The fact that yoghurt E had an 367 
IC50 lower than that of milk, indicates that fermentation of milk with S. thermophilus plays a 368 
significant role in the bioactivity of polar lipids present in these yoghurts.  369 
 Functional analysis of the shotgun metagenomics data was performed using 370 
HUMAnN2, which indicated that the microbial species present in all yoghurts had the 371 
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metabolic capacity to synthesise polar lipids and various fatty acids (Fig. 2.). It is already well 372 
documented that certain lactic acid bacterial strains have a distinctive phospholipid 373 
composition, that may be distinguishable between different genera (Exterkate, Otten, 374 
Wassenberg, & Veerkamp, 1971). In particular, based on the abundances of GO terms detected 375 
by HUMAnN2, S. thermophilus in yoghurt D seems to have the greatest capacity to synthesise 376 
fatty acids and phospholipids and possess the genes for other functions in relation to the 377 
metabolic processes of fatty acids and polar lipids including: phosphatidylserine decarboxylase 378 
activity (GO:0004609); phosphatidylethanolamine biosynthetic process (GO:0006631); 379 
glycerophospholipid metabolic process (GO:0006650); phospholipid biosynthetic process; 380 
(GO:0008654) cardiolipin synthase activity (GO:0008808); cardiolipin biosynthetic process 381 
(GO:0032049); acetyl-CoA carboxylase complex (GO:0009317); glycerol-3-phosphate 382 
cytidyltransferase activity (GO:0047348); biotin carboxylase activity (GO:0004075); lipid 383 
biosynthetic process (GO:0008610) (Fig. 2.). Several of the genes associated with anabolic 384 
processes that are crucial for the biosynthesis of various polar lipids and are present in varying 385 
amounts in each of the yoghurts.  386 
 In particular, it seems that L. delbrueckii subsp. bulgaricus has the genetic capacity to 387 
express CDP-diacylglycerol-glycerol-3-phosphate 3-phosphatidyltransferase activity 388 
(GO:0008444), which is involved in the biosynthesis of phospholipids by catalysing the 389 
conversion of CDP-diacylglycerol and glycerol-3-phosphate to CMP and 3-(3-phosphatidyl)-390 
glycerol 1-phosphate in the committed step to the synthesis of acidic phospholipids (Gaynor et 391 
al., 1991; Vance & Vance, 2008). Furthermore, the detection of GO terms associated with the 392 
phosphatidylethanolamine (PE) (GO:0006646) and cardiolipin (CL) (GO:0008808) 393 
biosynthesis is not unexpected due to their respective roles in the bacterial and mitochondrial 394 
membranes (Vance & Vance, 2008).  395 
 Interestingly, yoghurt D exhibited the greatest capacity for glycerol ether metabolic 396 
processes. As these lipids exhibit similar structures to PAF, yoghurts that contain these lipids 397 
may induce either agonistic or antagonistic effects, but both cardioprotective (Tsoupras, 398 
Lordan, & Zabetakis, 2018); structural elucidation of these polar lipid extracts will provide 399 
more information about the structure function relationship between these polar lipids and the 400 
PAF-R. Moreover, the detection of genes associated with the synthesis various phospholipid 401 
including PE and CL in the HUMAnN2 output may explain the levels of bioactivity detected 402 
in these yoghurt as these phospholipids have previously been associated with potent 403 
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antithrombotic properties in polar lipids of dairy products (Megalemou et al., 2017; Poutzalis 404 
et al., 2016). 405 
 The abundance of level-4 EC categories of interest was also assessed (Fig. 3.). It is clear 406 
that the microbes present in each of the yoghurts play a key role in the alteration of the overall 407 
fatty acid composition of the yoghurts. Several of the EC categories of interest detected are 408 
responsible for the biosynthesis of fatty acids (EC 6.4.1.2: Acetyl-CoA carboxylase), which 409 
although expected, are present in abundance. There are also numerous EC categories detected 410 
in abundance that are specific to phospholipid biosynthesis. For example glycerol-3-phosphate 411 
acyltransferase (EC 2.3.1.n3) and phosphate acyltransferase (EC 2.3.1.n2) are the rate limiting 412 
enzymes for phosphatidic acid synthesis, which is critical for the synthesis of phospholipids 413 
(Wendel, Lewin, & Coleman, 2009). Both of these EC terms were detected in abundance in 414 
yoghurt D, which corresponds with the yoghurt that exhibited significant changes in the TPL 415 
lipid composition and the most potent bioactivity. Similarly, the detection of 416 
phosphatidylserine decarboxylase (EC 4.1.1.65), glycerol-3-phosphate cytidyltransferase (EC 417 
2.7.7.39), inositol-3-phosphate synthase (EC 5.5.1.4), and CDP-diacylglycerol-glycerol-3-418 
phosphate 3-phosphatidyltransferase (EC 2.7.8.5) indicates that the starter cultures in these 419 
yoghurts have the ability to synthesise phospholipids. However, further research is required to 420 
establish to what extent these starter cultures influence the phospholipid content of these 421 
yoghurts and whether they are incorporated into the dairy matrix or remain bound 422 
intracellularly.  423 
 Systemic inflammation is mediated by proinflammatory molecules such as PAF, which 424 
leads to the development of chronic conditions such as atherosclerosis and subsequently CVD 425 
(Moss et al., 2018; Tsoupras, Lordan, & Zabetakis, 2018). Therefore, considering diet and 426 
lifestyle are key modifiable risk factors for the prevention of CVD, the formulation of novel 427 
nutraceutical and functional foods to combat these inflammatory processes is imperative. 428 
Ovine milk is an underutilised nutritious milk with the potential to be used for functional food 429 
development (Balthazar et al., 2017). Previous research indicates that polar lipids in ovine 430 
yoghurts possess anti-PAF activity (Megalemou et al., 2017) and that the fermentation of milk 431 
may affect the antithrombotic properties of these bioactive lipids (Lordan & Zabetakis, 2017a).  432 
 As demonstrated in table 2, following milk fermentation and depending on the starter 433 
culture used, the IC50 decreased when milk was fermented to yoghurt, indicating an 434 
enhancement of the antithrombotic activity of the polar lipids. All of the yoghurt TPL had an 435 
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IC50 value lower than 85 µg, indicating that they all possessed potent antithrombotic properties, 436 
which is within range of previous polar lipids of animal origin tested on human PRP in vitro 437 
(Poutzalis et al., 2018; Tsoupras, Lordan, Demuru, et al., 2018) and dairy derived polar lipids 438 
tested on washed rabbit platelets in vitro (Megalemou et al., 2017; Poutzalis et al., 2016; 439 
Tsorotioti et al., 2014). In particular, yoghurts B and D possessed the lowest IC50 values, where 440 
the IC50 of yoghurt D was statistically significantly (p <  0.05) lower than all other samples 441 
tested. These yoghurts in particular contained a higher abundance of L. acidophilus, which 442 
seems to correlate with greater biological activity against PAF-induced platelet aggregation. 443 
Notably, L. acidophilus has previously been associated with anti-inflammatory activities 444 
against PAF; soluble factors released by L. acidophilus have been shown to alleviate PAF-445 
induced inflammation in human colonic NCM460 and Caco-2 cells by reducing nuclear factor 446 
kappa B (NF-κB) activation and IL-8 production (Borthakur et al., 2013). L. acidophilus has 447 
also demonstrated anti-inflammatory effects in vivo via impairing both the NF-κB and  448 
mitogen-activated protein kinase (MAPK) signalling pathways (Haihua Li et al., 2016).  449 
 Research shows that the fatty acid composition of polar lipids affects their 450 
antithrombotic capacity against PAF (Lordan et al., 2017). Following GC-MS analysis (Table 451 
3), it is evident that the microbial starter cultures play a key role in augmenting the polar lipid 452 
composition of ovine milk following bacterial fermentation, which in turn altered the 453 
antithrombotic capacity of the ovine milk polar lipids. Previous research has shown that as 454 
bovine or ovine milk is fermented to yoghurt, cheese, or kefir, the fatty acid composition 455 
changes due to lipolysis of existing milk lipids and synthesis of lipids by lactic acid bacteria 456 
(Florence et al., 2012; Guzel, Yibar, Belenli, Cetin, & Tanriverdi, 2017; Reguła, 2007; Vieira 457 
et al., 2015; Yadav, Jain, & Sinha, 2007). In comparison to the milk TPL, there were significant 458 
changes in the fatty acid composition of the TPL of all 5 yoghurts following fermentation with 459 
various starter cultures. Fermentation reduced the PUFA and increased the MUFA levels of the 460 
fatty acids of the polar lipids, whereas the levels of SFA varied depending on the yoghurt 461 
produced. Florence et al. (2012) demonstrated that increases in unsaturated fatty acids during 462 
milk fermentation was related to an improvement of L. delbrueckii subsp. bulgaricus growth 463 
and that the metabolism of various bacterial cultures modified the fatty acid profile of the milk.  464 
 There was a significant increase in the levels of 18:2 fatty acids in the TPL. Many of 465 
these 18:2 fatty acids are classed as conjugated linoleic acids (CLA) that are associated with 466 
various health benefits including anti-inflammatory (Lordan & Zabetakis, 2017a) and 467 
antithrombotic effects (Truitt, McNeill, & Vanderhoek, 1999). There was also a significant 468 
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increase in the levels of 20:4 and 22:5 in the polar lipid fatty acid composition of all the 469 
yoghurts, which may be associated with the enhanced antithrombotic activities of the yoghurts 470 
in contrast to the ovine milk. It is noteworthy that in marine products, it has been demonstrated 471 
that these ω3 PUFA are more bioactive when incorporated in a phospholipid structure rather 472 
than their free fatty acid forms (Lordan et al., 2017). Remarkably, the fatty acid composition 473 
of the polar lipids in yoghurt D contained several similarities to the classical PAF structure. 474 
PAF is generally composed of 16:0 (68 %), 18:0 (27 %), or 18:1 (4 %) at the sn-1 position 475 
(Demopoulos, Pinckard, & Hanahan, 1979), with acetic acid esterified to the sn-2 position, and 476 
phosphocholine group at the sn-3 position, whereas the three major fatty acids present in the 477 
polar lipids of yoghurt D were 16:0 (21.6 %), 18:0 (15.1 %), and 18:1 (23.0 %) (Demopoulos 478 
et al., 1979). However, further research is required to confirm if there is structural homology 479 
between these polar lipids and PAF.   480 
 Finally, as presented in Fig. 4. it seems that the capacity to produce bacteriocins, which 481 
are antimicrobial peptides produced by bacterial cultures, may correlate with greater 482 
antithrombotic activities. Some bacteriocins such as colicins, which is present in yoghurts D 483 
and E are often encoded with a lysis protein, which increases the permeability of the outer 484 
membrane of the producer organism and is lethal to the producing cells (Snijder & Dijkstra, 485 
2000). Consequently, it is possible that bacteriocins may play a role in releasing phospholipids 486 
into the yoghurt matrix. Several bacteriocins, for example cinnamycin (Machaidze & Seelig, 487 
2003), seem to demonstrate specificity for PE (Moll, Konings, & Driessen, 1999), which is the 488 
second most abundant phospholipid in most biological membranes (Lordan et al., 2017). 489 
Several bacteriocins have demonstrated selective binding towards negatively charged 490 
phospholipids on the membranes of cancer cells (Kaur & Kaur, 2015). Some bacteriocins do 491 
not seem to bind to neutral choline-containing zwitterionic PC molecules (Chatterjee, Paul, 492 
Xie, & van der Donk, 2005), and changes to the overall charge of phospholipids due to a change 493 
in the lipid composition is associated with bacteriocin resistance in some bacteria (Kuipers, 494 
Rink, & Moll, 2011), indicating that the phospholipid charge is a defining feature for 495 
bacteriocin specificity. 496 
 Because bacteriocins can permeabilise the phospholipid bilayer of microbial cells 497 
(Cotter, Hill, & Ross, 2005; O'Shea et al., 2012), it is possible that phospholipids from damaged 498 
or lysed bacterial cells may be released to the surrounding matrix, thus increasing their 499 
bioavailability. However, bacteriocins may also have the capacity to interact with the milk fat 500 
globule membrane (MFGM). Research has shown that when nisin was added to milk to reduce 501 
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the levels of microbial cells it became unavailable to destroy these cells but was bioavailable 502 
and active again when a detergent was added to permeabilise the MFGM (Jung, Bodyfelt, & 503 
Daeschel, 1992). Considering there is a wealth of evidence to suggest that bacteriocins can 504 
bind to various types of membranes, there is speculative evidence to suggest that the 505 
bacteriocins produced by the starter cultures in this study may interact with the MFGM 506 
increasing the levels of bioavailable phospholipids, however further research is required. 507 
 Overall, the present study has some limitations, and further research is required to 508 
reveal the molecular mechanisms by which polar lipids bind to the PAF-R and inhibit the 509 
proinflammatory actions of PAF. While the data relating to the bacteriocins is promising, 510 
further research is required to confirm these observations. In addition, clinical studies are 511 
required to assess the bioavailability of the antithrombotic polar lipids following consumption 512 
of the antithrombotic ovine yoghurts.  513 
 514 
5. Conclusions 515 
This study confirms that specific starter cultures can alter the fatty acid composition of dairy 516 
polar lipids during fermentation through the lipolysis and biosynthesis of fatty acids. By 517 
altering the polar lipid composition, the antithrombotic properties of these yoghurts have been 518 
enhanced. Further research is required to discern the exact polar lipid structures responsible for 519 
these bioactivities and how fermentation influences the phospholipid structure of milk polar 520 
lipids. Shotgun metagenomic characterisation of the yoghurts indicates that the use of L. 521 
acidophilus and S. thermophilus plays a key role in improving the antithrombotic properties of 522 
these yoghurts. Moreover, functional analysis indicates that the starter cultures present in these 523 
yoghurts have the metabolic capacity to synthesise and alter various polar lipids, therefore 524 
further research is required to discern whether these polar lipids are bioavailable in human 525 
studies. The presence of bacteriocin related genes in some of the most bioactive yoghurts also 526 
warrants further investigation to reveal if there are potential interactions between bacteriocins 527 
and the MFGM. In addition, structural elucidation of these antithrombotic polar lipids and the 528 
optimisation of the fermentation process may allow for the enhancement of the antithrombotic 529 
and anti-inflammatory health benefits of these ovine yoghurts. Similarly, further studies are 530 
required to assess the use of various milk sources and animal diets that may alter the milk polar 531 
lipid composition and antithrombotic properties. This study highlights that ovine milk and 532 
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yoghurts may have beneficial effects for human cardiovascular health and may lead to the 533 
future development of functional foods and nutraceuticals.  534 
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Fig. 1. (A) a stacked bar chart presenting the species-level microbial profile of yoghurts A-E 855 
as determined by 16s rRNA gene sequencing. (B) A Bray-Curtis MDS plot based on the 856 
MetaPhlAn2 output on the right that demonstrates that the microbial composition of yoghurts 857 
D and E are similar, yoghurts B and C are more similar to each other, whereas the microbial 858 
composition of yoghurt A is dissimilar to all the other yoghurts.      859 
26 
 
Fig. 2. The depicts the abundance of GO terms of interest in each yoghurt according to the 860 
corresponding bacterium associated with the GO term using HUMAnN2 output. 861 
27 
 
 862 
Fig. 3. The abundance of level-4 EC categories of interest in each yoghurt according to the 863 
corresponding bacterium associated with the GO term using HUMAnN2 analysis. 864 
 865 
 866 
 867 
 868 
 869 
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Fig. 4. (A) The total number of hits per class of bacteriocin for yoghurts A-E. Type II 870 
bacteriocins are in a greater abundance in all yoghurt samples. (B) A breakdown of the most 871 
abundant bacteriocin genes detected in each yoghurt.  872 
 873 
 874 
 875 
 876 
 877 
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Table 1  878 
The composition of the starter cultures used in the inoculation of ovine milk to produce 879 
yogurts A-E.  880 
Yogurt Cultures 
A 0.020 % w/v Streptococcus thermophilus and Lactobacillus delbrueckii subsp. 
bulgaricus (YC-380, Chr. Hansen, Denmark). 
B 0.015 % w/v Streptococcus thermophilus, Lactobacillus delbrueckii, subsp. 
bulgaricus, Lactobacillus acidophilus, and Bifidobacterium animalis subsp. lactis 
(YOMIXTM-205 LYO 250 DCU, Danisco, Denmark). 
 
C 0.015 % w/v Streptococcus thermophilus, Lactobacillus delbrueckii subsp. 
bulgaricus, Lactobacillus acidophilus, and Bifidobacterium animalis subsp. lactis 
(YOMIXTM-205 LYO 250 DCU, Danisco, Denmark) with an additional 0.020 % 
w/v Bifidobacterium animalis subsp. lactis (BB-12, Chr. Hansen, Denmark). 
 
D 0.015 % w/v Streptococcus thermophilus, Lactobacillus delbrueckii subsp. 
bulgaricus, Lactobacillus acidophilus and Bifidobacterium animalis subsp. lactis 
(YOMIXTM-205 LYO 250 DCU, Danisco, Denmark) with an additional 0.020 % 
w/v Lactobacillus acidophilus (LA-5, Chr. Hansen, Denmark). 
 
E 0.015 % w/v Streptococcus thermophilus, Lactobacillus delbrueckii subsp. 
bulgaricus, Lactobacillus acidophilus and Bifidobacterium animalis subsp. lactis 
(YOMIXTM-205 LYO 250 DCU, Danisco, Denmark),with an additional 0.020 % 
w/v Lactobacillus paracasei subsp. paracasei (L-431, Chr. Hansen, Denmark). 
 
  881 
 882 
 883 
 884 
 885 
 886 
 887 
 888 
 889 
 890 
 891 
 892 
 893 
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 894 
Table 2  895 
Content of total lipids (TL), expressed in grams per 100g of sheep milk and yoghurts (mean ± 896 
SD, n = 3), total polar lipids (TPL), and total neutral lipids (TNL), expressed as percentages of 897 
TL in the sheep milk and yoghurt samples (mean ± SD, n = 3). 898 
abDifferent superscripts indicate significant differences among different yoghurt samples within the same lipid 899 
classes when means are compared using a Fisher’s LSD multiple comparison test (p < 0.05).  900 
 901 
 902 
 903 
 904 
 905 
 906 
 907 
 908 
 909 
 910 
 911 
 912 
 913 
 914 
 915 
 916 
 917 
 918 
 919 
 920 
Sample TL (g/100g) TNL (%TL) TPL (%TL) 
Sheep Milk 5.28 ± 0.37a 95.15 ± 2.30a 3.20 ± 0.56b 
Yoghurt A 8.10 ± 0.43b 96.46 ± 1.07a 2.45 ± 0.20ab 
Yoghurt B  8.23 ± 1.59bc 97.62 ± 0.22a 2.29 ± 0.17a 
Yoghurt C 7.23 ± 0.60b 97.47 ± 0.53a   2.10 ± 0.37a 
Yoghurt D 7.47 ± 0.36b 97.34 ± 0.47a   2.25 ± 0.10a 
Yoghurt E  9.20 ± 0.55bc 97.60 ± 0.38a        2.55 ± 0.45ab 
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Table 3  921 
Fatty acid profile of total polar lipids (TPL) of milk and each yoghurt expressed in percentage 922 
(%) of total fatty acids of each sample (mean ± SD, n = 3). Total saturated fatty acids (SFA), 923 
monounsaturated fatty acids (MUFA) and polyunsaturated fatty acids (PUFA) are shown as a 924 
percentage of total lipid. 925 
abcdef Mean values (n = 3), ± standard deviation with different letters in the same row indicating statistical 926 
significant differences when means are compared using Fisher’s LSD multiple comparison test (p < 0.05). ND: 927 
non-detectable 928 
 929 
  930 
Fatty Acids A B C D E Milk 
 
8:0 ND 0.22 ± 0.14a 0.35 ± 0.08a ND 0.25 ± 0.07a 0.76 ± 0.66a 
9:0 ND 0.12 ± 0.05a ND ND ND 0.14 ± 0.07a 
10:0 3.14  ± 0.32b 4.90 ± 0.89c 4.66 ± 0.56c 1.60 ± 0.12a  3.35 ± 0.65bc 5.58 ± 1.78c 
10:1 0.17  ± 0.03b  0.22 ± 0.06bc 0.34 ± 0.13c 0.07 ± 0.01a  0.20 ± 0.04bc  0.28 ± 0.11bc 
11:0 0.13  ± 0.02a  0.29 ± 0.06bc   0.14 ± 0.12abc 0.20 ± 0.01b  0.17 ± 0.03ab 0.30 ± 0.08c 
12:0 3.90  ± 0.50a 5.06 ± 0.82ab 5.51 ± 0.85b 5.20 ± 0.32b  4.54 ± 0.54ab  4.93 ± 0.73ab 
12:1  0.15  ± 0.05bc 0.12 ± 0.05ab   0.12 ± 0.07abc 0.20 ± 0.01c 0.20 ± 0.01c 0.06 ± 0.01a 
13:0 0.21  ± 0.02a 0.32 ± 0.08bc 0.31 ± 0.02b 0.36 ± 0.02c 0.18 ± 0.03a  0.32 ± 0.05bc 
14:0 8.20  ± 0.59a 11.38 ± 0.28c 13.89 ± 1.17d 11.49 ± 0.78c 9.83 ± 0.96ab 8.87 ± 1.00ab 
14:1ω7 c9  0.28  ± 0.08abc 0.34 ± 0.01c 0.32 ± 0.05bc 0.42 ± 0.15bc  0.31 ± 0.01b 0.19 ± 0.01a 
15:0 1.33  ± 0.08b 1.93 ± 0.22a   1.31 ± 0.39abc 1.70 ± 0.20c 1.39 ± 0.07b 1.56 ± 0.10c 
16:0 17.53 ± 0.32a 19.87 ± 0.48b 20.43 ± 0.65bc 21.62 ± 0.60c 19.53 ± 1.56bc 17.20 ± 0.76a 
16:1ω7 c9 2.00  ± 0.14c 2.53 ± 0.35d 1.40 ± 0.18b 2.09 ± 0.31cd  1.71 ± 0.66bcd 0.88 ± 0.06a 
17:0 0.90  ± 0.01c 1.07 ± 0.15d 0.75 ± 0.09b 0.96 ± 0.05bd   0.96 ± 0.27bcd 0.45 ± 0.01a 
17:1 0.61  ± 0.01c 0.67 ± 0.13c 0.27 ± 0.17b 0.65 ± 0.12c  0.72 ± 0.30bc 0.02 ± 0.01a 
18:0 10.93± 0.68b 11.25 ± 1.25b 15.76 ± 2.64c 15.13 ± 1.17c 8.25 ± 0.27a 11.32 ± 0.72b 
18:1ω9 c9 35.56 ± 1.40c 27.62 ± 1.36b 23.61 ± 0.31ab 22.97 ± 1.63a  30.53 ± 3.74bc 23.59 ± 3.56ab 
18:2ω6 c9, t12 6.31  ± 0.02c  5.67 ± 0.67abc 4.89 ± 0.33a 5.95 ± 0.06b   5.50 ± 1.70abc 9.23 ± 0.64d 
18:2ω7 c9, t11 3.51  ± 0.16d 1.94 ± 0.12ab 1.47 ± 0.35a 2.00 ± 0.06b 3.29 ± 0.60d 2.56 ± 0.02c 
18:2ω6 t10, c12 0.46  ± 0.35b ND 0.05 ± 0.01a ND 0.93 ± 0.18b ND 
18:3ω3 c9, c12, c15 2.15  ± 0.01d 1.44 ± 0.16b 0.98 ± 0.16a 1.83 ± 0.05c 2.66 ± 0.13f 2.30 ± 0.16e 
20:0 ND 0.31 ± 0.01a 0.24 ± 0.15a 0.29 ± 0.11a ND ND 
20:1ω9 c9 0.65 ± 0.04a 0.79 ± 0.06b  0.74 ± 0.14ab 0.87 ± 0.04b   0.79 ± 0.44abc 1.01 ± 0.03c 
20:3ω9 c5, c8, c11 ND 0.24 ± 0.01a 0.37 ± 0.12a 0.20 ± 0.13a 0.32 ± 0.18a ND 
20:4ω6 c5, c8, c11, c14  0.95 ± 0.15c 0.49 ± 0.04a 0.61 ± 0.10b 0.57 ± 0.01b 1.20 ± 0.36c ND 
20:5ω3 c5, c8, c11, c14, c17 0.35 ± 0.03c 0.25 ± 0.01a 0.22 ± 0.08ab 0.29 ± 0.01b 0.42 ± 0.05d 3.15 ± 0.30e 
22:1 c11 0.53 ± 0.05a 0.82 ± 0.15bc 0.56 ± 0.22ab 1.00 ± 0.04c 0.72 ± 0.21ab 0.89 ± 0.11b 
22:4ω6 c7, c10, c13, c16 ND 0.14 ± 0.02a  0.25 ± 0.17ab ND 0.44 ± 0.04b ND 
22:5ω6 c4, c7, c10, c13, c16 1.62 ± 0.30b 0.97 ± 0.11a 0.96 ± 0.20a 1.54 ± 0.07b 1.67 ± 0.14b ND 
22:6ω3 c4, c7, c10, c13, c16, 
c19 
0.91 ± 0.37c 0.28 ± 0.03a  0.61 ± 0.36abc 0.44 ± 0.04b 0.58 ± 0.10b 0.97 ± 0.04c 
 
Total SFA 46.27 ± 1.54a 56.72 ± 1.33c 63.31 ± 2.62d 58.56 ± 0.89c 48.44 ± 3.88ab  54.01 ± 4.28bc 
Total MUFA 39.96 ± 1.37c 32.90 ± 1.06b 27.50 ± 0.48a 27.90 ± 0.62a 35.18 ± 3.84bc 27.35 ± 3.35a 
Total  ω7 5.782 ± 0.22c  4.805 ± 0.49b 3.196 ± 0.48a 4.519 ± 0.47b  5.309 ± 0.65bc 3.638 ± 0.07a 
Total  ω9 36.22 ± 1.39c 28.65 ± 1.42b 24.72 ± 0.27a 24.05 ± 1.73a  31.64 ± 4.03bc  24.60 ± 3.56ab 
Total PUFA 16.37 ± 0.60c  11.46 ± 0.97a 10.42 ± 0.29a 12.83 ± 0.18b 17.01 ± 1.56cd 18.22 ± 1.17d 
Total  ω3 3.431 ± 0.38c 1.970 ± 0.16a 1.819 ± 0.36a 2.562 ± 0.07b 3.662 ± 0.17c 6.420 ± 0.45d 
Total  ω6 9.345 ± 0.38c 7.270 ± 0.68a   6.763 ± 0.26a 8.057 ± 0.01b 9.738 ± 1.17c 9.228 ± 0.64c 
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Table 4  931 
Inhibition of PAF-induced platelet aggregation in human PRP by sheep milk and yogurts  total 932 
lipids (TL), total polar lipids (TPL), and total neutral lipids (TNL) produced by various starter 933 
cultures. This activity is represented by their IC50 (µg) (mean ± SD, n = 3). 934 
abcd Mean values (n = 3), ± standard deviation with different letters in the same column indicating statistical 935 
significant differences when means are compared using Fisher’s LSD multiple comparison test (p < 0.05). ND: 936 
not-detectable 937 
  938 
 939 
Yogurt TL  TNL TPL 
A  306.5    ±    64.1ab 2938   ±   123a 77.00    ±    9.20c 
B 331.7    ±    27.3b 738.6   ±   37.7b 57.41    ±    5.93b 
C  253.9    ±    73.1ab  ND 70.72    ±    3.95c 
D 224.5    ±    21.4a 640.9   ±   34.0c 44.84   ±    4.96a  
E  263.8    ±    55.5ab  ND  68.10    ±    7.55bc 
Milk 378.0    ±    12.8c  ND    154.4    ±    12.8d 
